The synthesis of the aryldiphosphonic ester C6H2[P(O)(OEt)2]2-1,3-t-Bu-5 (2) and of its organotin derivatives C6H2[P(O)(OEt)2]2-2,6-t-Bu-4-RR‘2Sn-1 (5, R = R‘ = Me; 6, R = R‘ = Ph; 7, R = Ph, R‘ = Cl; 8, R = Ph, R‘ = Br) is reported. Also reported is the preparation of the organosilicon and organotin compounds C6H2[P(O)(OEt)2]2-2,4-Me3Si-1 (3), C6H2[P(O)(OEt)2]2-2,4-(Me3Si)2-1,5 (4), C6H3[P(O)(OEt)2]2-2,4-Ph2RSn-1 (9, R = Ph; 12, R = Br), and C6H3[P(O)(OEt)2]2-2,4-(Ph2RSn)2-1,5 (10, R = Ph; 11, R = Br). X-ray investigations reveal weak intramolecular Sn−O interactions for 6 (2.865(3)−3.063(4) Å), 9 (2.803(3) Å), and 10 (2.793(2) Å) but strong Sn−O coordinations for 7 (2.203(5)/2.278(6) Å) and 11 (2.379(3)/2.412(3) Å), indicating the high donor capacity of the new rigid O,C,O- and O,C-chelating ligands in these compounds. NMR studies confirm that the basic coordination geometry found in the solid state is maintained in solution.
No takes yet. Share an insight, caveat, or question.
Mehring et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: